Masatoshi Kudo

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1174 publications

Toward Global Harmonization of EUS-Guided Biliary Drainage: A Step Beyond Regional Consensus.

Toward Global Harmonization of EUS-Guided Biliary Drainage: A Step Beyond Regional Consensus.

Journal: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society

Published: June 18, 2026

Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization.

Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization.

Journal: Antibodies (Basel, Switzerland)

Published: June 17, 2026

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Journal: BMJ open

Published: June 02, 2026

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Half-release and full aspiration technique for endoscopic ultrasound-guided hepaticogastrostomy in severe acute cholangitis.

Half-release and full aspiration technique for endoscopic ultrasound-guided hepaticogastrostomy in severe acute cholangitis.

Journal: Endoscopy

Published: May 19, 2026

Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma.

Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma.

Journal: Liver cancer

Published: May 13, 2026

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Journal: Future oncology (London, England)

Published: May 11, 2026

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Journal: The Lancet. Oncology

Published: May 08, 2026

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: May 07, 2026

Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.

Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.

Journal: BMC gastroenterology

Published: May 06, 2026

Beyond Equivalence: Reconsidering the Role of EUS-Guided Gallbladder Drainage in the Post-ERCP Failure Algorithm.

Beyond Equivalence: Reconsidering the Role of EUS-Guided Gallbladder Drainage in the Post-ERCP Failure Algorithm.

Journal: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society

Published: April 23, 2026

A novel cancer gene therapy achieving reciprocal regulation of PTEN and PARP1 expression.

A novel cancer gene therapy achieving reciprocal regulation of PTEN and PARP1 expression.

Journal: Molecular therapy. Oncology

Published: April 22, 2026

Showing 1-12 of 1,174

Last Updated: 09/26/2026